Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) EBITDA: 2010-2021

Historic EBITDA for Neurocrine Biosciences (NBIX) over the last 12 years, with Sep 2021 value amounting to $22.2 million.

  • Neurocrine Biosciences' EBITDA rose 137.63% to $22.2 million in Q3 2021 from the same period last year, while for Sep 2021 it was $36.5 million, marking a year-over-year decrease of 61.56%. This contributed to the annual value of $40.4 million for FY2019, which is 91.91% up from last year.
  • According to the latest figures from Q3 2021, Neurocrine Biosciences' EBITDA is $22.2 million, which was down 47.14% from $42.0 million recorded in Q2 2021.
  • Neurocrine Biosciences' 5-year EBITDA high stood at $85.6 million for Q2 2020, and its period low was -$100.4 million during Q1 2019.
  • For the 3-year period, Neurocrine Biosciences' EBITDA averaged around $19.7 million, with its median value being $34.2 million (2019).
  • As far as peak fluctuations go, Neurocrine Biosciences' EBITDA plummeted by 323.51% in 2017, and later surged by 1,138.81% in 2019.
  • Quarterly analysis of 5 years shows Neurocrine Biosciences' EBITDA stood at $5.6 million in 2017, then spiked by 226.32% to $18.2 million in 2018, then spiked by 85.46% to $33.8 million in 2019, then slumped by 207.66% to -$59.0 million in 2020, then soared by 137.63% to $22.2 million in 2021.
  • Its EBITDA stands at $22.2 million for Q3 2021, versus $42.0 million for Q2 2021 and $31.3 million for Q1 2021.